Altamira Therapeutics Ltd. (NASDAQ:CYTO) Sees Large Decrease in Short Interest

Altamira Therapeutics Ltd. (NASDAQ:CYTO) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 82,000 shares, a decrease of 54.5% from the August 31st total of 180,200 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily volume of 444,400 shares, the short-interest ratio is presently 0.2 days.

Altamira Therapeutics Stock Up 0.4 %

NASDAQ CYTO traded up $0.00 during trading on Thursday, hitting $0.67. The stock had a trading volume of 27,332 shares, compared to its average volume of 878,089. Altamira Therapeutics has a one year low of $0.67 and a one year high of $17.20. The stock has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.34.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.